AIkido Pharma (AIKI)

Management Discussion

• The Company experienced very little or no revenue in the last two years and we don’t expect any revenue until a biotechnology product is fully developed which may not occur for many years.
• For the year ended December 31, 2021 and 2020, we incurred a loss from operations of $9.4 million and $6.5 million, respectively. The increase in loss was primarily attributed to $3.6 million increase in general and administrative expenses, partially offset by $0.5 million decrease in research and development expense incurred in connection with the license acquired, and $0.3 million decrease in other research and development expense. In 2021, we engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build our investment processes. Kyle Wool, Board Member, is the president of Revere. We incurred fees of approximately $1.2 million during the year December 31, 2021. These fees were included in general and administrative expense.
• For the year ended December 31, 2021 and 2020, other income was approximately $2.3 million and $ Other expenses was approximately $5.8 million, respectively. The increase in other income was primarily attributed to a $10.4 million increase in fair value of investment, and partially offset by $2.7 million decrease in gains on marketable securities.